Drugs online research references
Ter Arkh. 2000;72(10):94-6.
[Efficacy of quadropril (spirapril) vs capropril in treatment of essential hypertension]
[Article in Russian]
Polimbetov DS, Kraisman VA, Isaeva BG, Aliev FR.
AIM: To compare the efficacy of monotherapy with quadropril (spirapril) vs captopril in essential hypertension. MATERIAL AND METHODS: 20 female patients aged 55 +/- 2 years with moderate hypertension (WHO classification) were included in the study. 16 patients had congestive heart failure stage II NYHA and 4 patients stage III NYHA. ECG and echocardiography were performed in all the patients. Two patient groups of 10 patients were treated for 6 weeks. Group 1 received 6 mg quadropril once daily. Group 2 received 25 mg captopril 3 times daily. The therapy was considered to be efficient if diastolic pressure (BP) was reduced to 90 +/- 5 mm Hg and systolic BP to 140 +/- 10 mm Hg from baseline values in the range of 210/120-170/100 mm Hg. RESULTS: The hypotensive effect of quadropril resulted in stabilisation of BP during the second week of therapy. A significant BP decrease was achieved at the end of 6 week therapy. Systolic BP fell from 178.8 +/- 3.2 to 145 +/- 5.6 mm Hd and diastolic BP from 109.7 +/- 1.2 to 92.4 +/- 1.7 mm Hg. Central and cardiac hemodynamic parameters improved. In one patient the condition improved from CHF stage III to stage II NYHA. No adverse effects were observed. A hypotensive effect of captopril reduced significantly systolic blood pressure from 182.1 +/- 2.7 to 150 +/- 4.6 mm Hg and diastolic BP from 110.4 +/- 1.1 to 100.1 +/- 1.9 mm Hg. Two patients developed adverse effects: cough and chest dyscomfort. CONCLUSION: Quadropril monotherapy showed to be more effective in diastolic BP decrease compared with captopril monotherapy and had advantages in one daily dose regimen, absence of the first dose effect and side effects.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11220890&dopt=Abstract
Klin Med (Mosk). 2000;78(10):37-40.
[Effects of antihypertensive drugs with different mechanism of action on cardiac hemodynamics in patients with artificial pacemaker]
[Article in Russian]
Iskenderov BG, Latyshev DS.
Cardiohemodynamic effects of obsidan, nifedipin, captopril and prasosine were compared when the drugs were given in a 4-week course regarding circulation type and stimulation regime to 74 patients with artificial pacemaker suffering from mild or moderate essential hypertension. A peculiar action of obsidan, nifedipin and prasosine in cardiac pacing found at echocardiography is explained by the absence of frequency-dependent (chronotropic) cardiohemodynamic effects. Obsidan lowered blood pressure most effectively in hyperkinetic circulation. Nifedipine, captopril and prasosine were more potent in eu- and hypokinetic circulation. Reduction of arterial pressure by the above peripheral vasodilators in patients with hyperkinetic circulation results from a fall of total peripheral vascular resistance initially elevated by 16.5%, on the average. In isolated ventricular stimulation (regime VVI) vs atrial one (AAI regime) hypotensive action of the above drugs was more potent, but side effects were more frequent.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11220897&dopt=Abstract
Clin Pharmacol Ther. 1985 Oct;38(4):462-8.
Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states.
Onoyama K, Hirakata H, Tsuruda H, Ohchi N, Tomooka S, Motomura K, Omae T, Hayashi K, Fujishima M.
The plasma concentration and urinary excretion of a newly developed angiotensin I converting enzyme inhibitor, alacepril (which is converted to captopril after absorption), were investigated in seven normal healthy subjects. Fifty milligrams of the drug was administered orally either in the fasting or in the fed state. In the fasting state, the time of maximal plasma concentration (tmax) was 1 hour for free captopril, 1.7 hours for protein-conjugated captopril, and 1.6 hours for total captopril. The biologic t1/2 of free, protein-conjugated, and total captopril was 1.9, 4.2, and 5 hours, respectively. In the fed state, neither tmax nor t1/2 changed, except that the tmax of free captopril was prolonged to 1.9 hours (P less than 0.01). Cumulative urinary excretion of free captopril at 8 hours was 35% of the drug administered in the fasting state and that of total captopril at 24 hours was 59%. These data did not differ significantly from those obtained after food intake. The biologic t1/2 of free captopril after alacepril dosing was longer than in previous studies of captopril per se. Because biologic or clinical effects have not been studied, it should be left conjectural whether alacepril is a longer-acting angiotensin I converting enzyme inhibitor. A prolonged effect of the drug can be expected by its administration after a meal.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3899460&dopt=Abstract
online pharmacies ||
Hair Million herbal formula for hair loss and hair growth ||
Amoxicillin ||
Tramadol ||
Paxil ||
Rx Drugs USA, Prescription Drugs Online Pharmacy ||
Zithromax ||
online pharmacy ||
Antibiotics and prescription medications online literature ||
Antibiotics